feedback

Course Director

Naiyer Rizvi, MD
Naiyer Rizvi, MD

Columbia University Medical Center
New York, New York

Faculty

Melissa L. Johnson
Melissa L. Johnson, MD

Sarah Cannon Research Institute
Nashville, Tennessee

Accredited by

Medical Learning Institute, Inc.

Activity Details

Credit Types:CME
Credit Amount:1.0 Credits
Release Date:2017-Dec-08
Expiration Date:2018-Dec-07
Estimated Time for Completion:60 minutes
Registration Required:No
Cost:Free of charge

Activity Description and Educational Objectives

Immunotherapy has become a key pillar in the treatment of advanced NSCLC, and a wide range of single-agent and combinatorial immune-based treatment approaches are being explored in various settings to assess their role and potential for further improving outcomes in patients with lung cancer. Based on a recent live symposium, this activity will highlight the current state of the science as well as new promising research directions, and provide practical guidance for effectively navigating the rapidly changing and complex lung cancer treatment landscape in the era of immuno-oncology.

Upon completion of this activity, participants should be better able to:

  • Analyze the efficacy and safety of immunotherapies and immune-based combinations in different types and settings of lung cancer based on the evidence from the latest clinical trials
  • Discuss the indications for and roles of immunotherapies and combinations in the treatment of different types and settings of lung cancer
  • Integrate immunotherapies either as monotherapies or as part of rational combinations into treatment plans for appropriate patients with lung cancer according to the latest evidence and recommendations
  • Refer patients with lung cancer to clinical trials assessing novel strategies with immunotherapies and combinations to further advance the field, address unmet needs, and improve patient outcomes

Target Audience

This activity has been designed to meet the educational needs of oncologists and other healthcare professionals as well as researchers involved in advancing the care of patients with lung cancer through optimal use of cancer immunotherapies.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. A score of 70% or higher is needed to obtain CME credit. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: December 08, 2017 - December 07, 2018
Time to Complete: 60 minutes

Faculty & Disclosure / Conflict of Interest Policy

Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Medical Learning Institute, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The associates of Medical Learning Institute, Inc., the accredited provider for this activity, and PVI, PeerView Institute for Medical Education do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME activity during the past 12 months.

Course Director and Moderator

Naiyer Rizvi, MD
Professor of Medicine
Director, Thoracic Oncology
Co-Director, Cancer Immunotherapy Program
Price Chair in Clinical Translational Research
Columbia University Medical Center
New York, New York

Naiyer Rizvi, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for AbbVie Inc.; AstraZeneca; Merck & Co., Inc.; Bristol-Myers Squibb; Eli Lilly and Company; F. Hoffmann-La Roche Ltd; Merck KGaA; Novartis Pharmaceuticals Corporation; and Pfizer.
Stock Shareholder in ARMO Biosciences; Gritstone Oncology where Dr. Rizvi is a Co-Founder.
Advisory Board for NeoGenomics Laboratories, Inc. and Nilogen Oncosystems.
Naiyer Rizvi, MD, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: cancer immunotherapies and immunotherapy-based combinations.

Faculty

Melissa L. Johnson, MD
Associate Director, Lung Cancer Research
Sarah Cannon Research Institute
Nashville, Tennessee

Melissa L. Johnson, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for Boehringer Ingelheim Pharmaceuticals, Inc.; Celgene Corporation; and Genentech, Inc./F. Hoffmann-La Roche Ltd. (All compensated to institution).
Grant/Research Support from AbbVie Inc.; Adaptimmune Therapeutics; Apexigen; Array BioPharma; AstraZeneca; BerGenBio; Checkpoint Therapeutics, Inc.; EMD Serono Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd; Genmab; Janssen Pharmaceuticals, Inc.; Kadmon Holdings, Inc.; Lilly; Mirati Therapeutics, Inc.; Merrimack Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; OncoMed Pharmaceuticals; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; Stemcentrx, Inc; and Tarveda Therapeutics. (All funding goes to institution).
Other Financial or Material Support from Spouse who is a contract lobbyist for Astellas Pharma, Inc. and Otsuka Pharmaceuticals Inc.
Melissa L. Johnson, MD, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: cancer immunotherapies and immunotherapy-based combinations.

CME Reviewer

Vishwanath Sathyanarayanan, MD, DM
Apollo Hospitals
Bangalore, Karnataka, India

Vishwanath Sathyanarayanan, MD, DM, has no financial interests/relationships or affiliations in relation to this activity.

Medical Director

Kadrin Wilfong, MD
PVI, PeerView Institute for Medical Education

Kadrin Wilfong, MD, has no financial interests/relationships or affiliations in relation to this activity.

Disclaimer

The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.

Providership, Credit & Support

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Providership

This CME activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.

Support

This activity is supported by an independent educational grant from AstraZeneca.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

About This CME Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

Copyright © 2000-2017, PeerView

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.